Mustang Bio announces publication of data from Phase 1 trial of MB-101

Mustang Bio announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma. Highlights from the data include: Stable disease or better was achieved in 50% of heavily pretreated patients for at least two months, with two partial responses, one complete response, and a second CR after additional CAR-T cycles under compassionate use. Patients with recurrent GBM treated in the final cohort with dual intratumoral/ intraventricular delivery and an optimized manufacturing process exhibited superior median overall survival of 10.2 months, compared to the expected survival rate of six months in patients with recurrent GBM. The median overall survival for all patients was eight months. Intermediate/high pre-treatment tumor T-cell levels that are indicative of a “hot” tumor microenvironment correlated with a significant survival benefit over negative/low pre-treatment tumor T-cell levels that are indicative of a “cold” TME. Overall, all routes of delivery were well-tolerated at doses up to 200106 CART-cells. Central nervous system increases in inflammatory cytokines, including IFNgamma, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.